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ABSTRACT
Sodium-glucose co-transporter-2 (SGLT2)
inhibitors are a newly developed class of oral
anti-diabetic drugs (OADs) with a unique
mechanism of action. This review describes
the biochemistry and physiology underlying
the use of SGLT2 inhibitors, and their clinical
pharmacology, including mechanism of action
and posology. The pragmatic placement of
these molecules in the existing OAD arena is
also discussed.
Keywords: Anti-diabetic drugs; Cardiovascular
safety; Canagliflozin; Dapagliflozin;
Empagliflozin; Perineal hygiene; Sodium-
glucose co-transporter-2 inhibitors
INTRODUCTION
Healthy individuals are able to maintain tight
glucose homeostasis by closely regulating
glucose production, reabsorption, and
utilization. The importance of this
homeostatic mechanism is evident from the
fact that, in spite of extreme variations in
glucose intake, relatively few people develop
either diabetes or hypoglycemia [1].
In people without diabetes, about 180 g of
glucose is filtered daily by the renal glomeruli,
and is then reabsorbed in the proximal
convoluted tubule (PCT). This is achieved by
passive transporters, namely, facilitated glucose
transporters (GLUTs), and active co-
transporters, namely, sodium-glucose co-
transporters (SGLTs). There are six identified
SGLTs, of which two (SGLT1 and SGLT2) are
considered most important [1]. These SGLTs are
described in Table 1 [2].
This review describes the biochemistry and
physiology underlying the use of SGLT2
inhibitors (SGLT2i), and their clinical
pharmacology, including mechanism of action
and posology, and discusses the pragmatic
placement of these molecules in the existing
oral anti-diabetic drug arena. The article is based
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on previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by the author.
HISTORY
The first SGLT2i discovered was phlorizin, a
naturally occurring compound derived from
apple tree bark. Because of its non-selective
nature, it caused severe gastrointestinal
symptoms. Due to this and to its poor oral
bioavailability, work on its development could
not continue [3]. Drugs which specifically
inhibit SGLT2, and thereby avoid
gastrointestinal effects related to SGLT1
inhibition, have now been developed, some of
which are listed in Table 2.
RATIONALE
Glucosuria (i.e., the excretion of glucose
through the kidneys) only occurs if the
maximal capacity of various glucose
transporter proteins (350 mg glucose/min) is
exceeded [2, 4]. Earlier, glucosuria was thought
to be a pathological mechanism, or a marker of
illness. However, one may approach this
condition from a different view point. Persons
with ambient hyperglycemia are at risk of
endothelial dysfunction and resultant
complications, due to the high levels of
glucose in circulation. Kidneys try to prevent
an excessive rise in blood glucose levels by
glucuresis, thereby mitigating the adverse
effects associated with high glucose levels.
Theoretically, compounds which promote
glucuresis should help to reduce circulating
Table 1 Comparison of SGLT1 and SGLT2
Characteristic SGLT1 SGLT2
Location Small intestine; later part of PCT
(segment 3)
Early PCT (segment 1, 2)
Capacity Low High
Afﬁnity High Low
Contribution to glucose reabsorption 10% 90%
Disease state if mutation/deﬁciency occurs Glucose-galactose malabsorption Familial renal glucosuria
Physical manifestations of disease state Diarrhea at few days age None
Course Fatal without glucose free/galactose
free diet
Benign
Inhibitors Phlorizin Currently available SGLT2i
PCT proximal convoluted tubule, SGLT sodium-glucose co-transporter, SGLT2i sodium-glucose co-transporter-2 inhibitors
Table 2 Sodium glucose co-transporters in advanced
development or already approved
Molecule Approval/development status
Canagliﬂozin 40 countries including EU, USA,
China, Russia
Dapagliﬂozin 40 countries including EU, USA,
Japan,
Empagliﬂozin Phase 3 [37]
Ipragliﬂozin Japan
Luseogliﬂozin Under review for approval in Japan
Tofogliﬂozin Phase 3 [43, 44]
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work by inhibiting SGLT2 in the PCT, to
prevent reabsorption of glucose and facilitate
its excretion in urine. As glucose is excreted, its
plasma levels fall leading to an improvement in
all glycemic parameters [4–6].
This mechanism of action is dependent on
blood glucose levels and, unlike the actions of
thiazolidinediones (mediated through GLUTs),
is independent of the actions of insulin. Thus,
there is minimal potential for hypoglycemia,
and no risk of overstimulation or fatigue of the
beta cells [7]. Because their mode of action relies
upon normal renal glomerular-tubular
function, SGLT2i efficacy is reduced in persons
with renal impairment.
CLINICAL PHARMACOLOGY
Dapagliflozin is rapidly absorbed after oral
administration, reaching peak plasma
concentration in 2 h, and exhibiting oral
bioavailability of 78% [8]. Dapagliflozin is
metabolized by uridine diphosphate-
glucuronosyltransferase (UGT)1A9 in both the
liver and kidneys [8]. Canagliflozin achieves
maximal plasma concentration 1–2 h after oral
administration (oral bioavailability 65%) and
steady state after 4–5 days. It is metabolized by
glucuronidation by UGT1A9 and UGT2B4 [9].
Empagliflozin reaches peak plasma
concentration 1.33–3.0 h after oral
administration, before declining in a biphasic
manner. The terminal half-life has been
calculated to be 10.3–18.8 h in multiple dose
studies, with steady state being achieved by day
6 [10]. No dosage adjustments are required in
renal or hepatic impairment. A summary of the
clinical pharmacology of SGLT2i is presented in
Table 3.
Dapagliflozin and canagliflozin have proven
efficacy in improving glycemic parameters,
both as monotherapy and in combination
[11]. A 52-week comparison between
canagliflozin 100 and 300 mg showed non-
inferiority, and canagliflozin 300 mg showed
statistical superiority to sitagliptin in lowering
glycated hemoglobin (HbA1c) [12].
Canagliflozin 100 mg and 300 mg reduced
bodyweight versus placebo at week 26 and
sitagliptin at week 52. The published results
are summarized in Table 4. Four-year (208-
week) use of dapagliflozin with metformin
produced a sustained and durable reduction in
blood glucose levels with significantly less
frequent adverse reactions as compared to
glimepiride with metformin. After 4 years, the
difference in HbA1c reduction between two
groups was -0.3% [95% confidence interval
(CI) -0.51, -0.09]. The trend over a period of
time showed further increase in the difference
with more prolonged use [13].
The long-term efficacy and safety of
empagliflozin have also been investigated as
add-on therapy to basal insulin. Patients with
type 2 diabetes mellitus (T2DM) were
randomized to receive empagliflozin 10 or
25 mg once daily or placebo; the basal insulin
regimen was kept constant for the first
18 weeks, after which the treating investigator
could adjust the regimen at their discretion for
the following 60 weeks [14]. As well as
significant improvements in HbA1c, patients
in both of the empagliflozin groups had
significant reductions in their insulin doses at
week 78, and also registered weight loss versus a
small weight gain in those receiving placebo
[14]. The decrease in insulin requirements in
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patients on dapagliflozin has been evaluated in
a study on insulin-mediated whole-body
glucose uptake and endogenous glucose
production using euglycemic hyperinsulinemic
clamp technique. Dapagliflozin treatment for
2 weeks increased insulin-mediated tissue
glucose disposal by 18% and resulted in an
increase in endogenous glucose production
(with increased fasting glucagon levels) [15].
PLEIOTROPIC EFFECTS
Sodium-glucose co-transporter-2 inhibitors use
leads to a reduction in body weight, ranging
from about 1 to 5 kg [16]. A greater fall is seen in
patients with long-standing diabetes and in
those with a higher baseline weight. This
weight loss is sustained after up to 2 years of
use of dapagliflozin, and may be linked to a
reduction in insulin dose requirements of
patients with long-standing diabetes [16].
Analysis of 208-week data comparing
dapagliflozin in combination with metformin
versus glimepiride in combination with
metformin showed 4.38 kg (95% CI -5.31,
-3.46) difference between two groups. Patients
in the glimepiride group gained a mean of
0.73 kg while those in dapagliflozin group lost
3.65 kg [13].
While it may be argued that weight loss is
because of volume depletion, it has been shown
that two-thirds of the decreased weight is lost
from fat mass (especially visceral abnormal fat),
as compared to lean mass [14]. An initially rapid
Table 3 Clinical pharmacology of sodium-glucose co-transporter-2 inhibitors
Molecule Dose range Oral
bioavailability
(%)
Elimination pathway Dose modiﬁcations
Dapagliﬂozin 5–10 mg
once daily
78 Hepatic and renal
UGT1A9
Should not be initiated in patients with
eGFR\60 ml/mt/1.73 m2




65 UGT1A9 and 2B4 Dose limited to 100 mg once daily in patients
with eGFR[45\60 ml/min/1.73 m2







Dose adjustment in patients with creatinine
clearance\60 ml/min
Contraindicated in patients with creatinine
clearance\45 ml/min





Dose limited to 100 mg once daily in patients
with eGFR[45\60 ml/min/1.73 m2
Not recommended in patients with
eGFR\45 ml/min/1.73 m2
eGFR estimated glomerular ﬁltration rate, N/a not available, UGT uridine diphosphate-glucuronosyltransferase
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decline in weight is followed by a slower rate of
weight loss, and is also marked by a reduction in
weight circumference. Concomitant use of
SGLT2i can attenuate or neutralize weight gain
due to insulin, if given in combination with
insulin [16].
Sodium-glucose co-transporter-2 inhibitors
also cause significant reductions in both
systolic and diastolic blood pressure (BP).
These changes are relatively more prominent
for systolic BP, are not dose dependent, and are
not characterized by concomitant tachycardia
or symptoms of hypotension/syncope in most
of the cases. The effects on BP seem to be
independent of glycemic or body weight
reduction, and are greater in patients with
high baseline systolic BP [17]. BP reduction
with SGLT2i occurs due to osmotic diuresis
initially, and to local rennin-angiotensin system
inhibition later on [18]. Some studies have
reported reduction of up to 13.4–17 mmHg in
systolic BP with empagliflozin, a magnitude
similar to that observed with many anti-
hypersensitive drugs [19, 20]. A recently
published 104-week outcome study of
canagliflozin showed that the 100 and 300 mg
dose reduced systolic and diastolic BP compared
with glimepiride, with no notable changes in
pulse rate [20]. Analysis of 208-week data
comparing dapagliflozin in combination with
metformin versus glimepiride with metformin
showed an increase of 0.2 mmHg (95% CI
-1.66, 1.61) in the glimepiride group while
those on dapagliflozin showed a reduction of
3.69 mmHg (95% CI -5.24, -2.14) [13].
Sodium-glucose co-transporter-2 inhibitors
are either lipid-friendly or lipid-neutral drugs.
Canagliflozin, for example, increases high-
density lipoprotein (HDL) by 7.1–10.6%, low-
density lipoprotein (LDL) by 7.1%, and reduces
triglycerides by 2.3% [21, 22]. Treatment with
canagliflozin for 104 weeks was also associated
with increases in HDL-C and LDL-C, which is
consistent with findings at week 52. However,
the proportion of patients who started or
modified therapy with lipid-modifying agents
were 13%, 11.5%, and 13.3% in the
canagliflozin 100 mg, canagliflozin 300 mg,





















HbA1c (%) -1.03 – -0.94 -0.79 -1.06 -1.03 -0.72
FPG (mg/dl) -35 – -27 – -31 -33 -25




HbA1c (%) -0.9 -2.0 -0.8 -0.8 -1.0 -0.4 -0.9
FPG (mg/dl) -28.8 -60.4 -23.5 -28.5 -29.6 -24.1 -21.7




HbA1c (%) -1.29 – -0.48 -1.14 -0.88 – –
FPG (mg/dl) -39.4 – – -38 -41 – –
FPG fasting plasma glucose, HbA1c glycated hemoglobin, Met metformin, MetXR metformin extended release, PPG post-
prandial plasma glucose, SU sulfonylurea, TZD thiazolidinedione
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and glimepiride groups, respectively [23]. After
4 years of use, sustained and stable weight loss
was observed with dapagliflozin versus weight
gain with glimepiride (-3.95 vs. ?1.12 kg).
Mean systolic BP was reduced with
dapagliflozin but not with glimepiride [24].
Data from 21 clinical studies, including 2
that exclusively enrolled patients with a history
of cardiovascular disease (CVD), were included
in a prespecified meta-analysis (n = 9,339) to
assess the cardiovascular (CV) safety of
dapagliflozin (2.5 mg to[10 mg/day;
n = 5,936) versus comparators (placebo or
active n = 3,403) [25]. The prespecified primary
end point was a composite of time to CV death,
myocardial infarction (MI), stroke, or
hospitalization for unstable angina. The
secondary end point included the primary end
point plus unplanned coronary
revascularization and hospitalization for heart
failure. The estimated hazard ratio (HR) using a
Cox proportional hazards method was 0.787
(95% CI 0.579, 1.070). Analyses of the
secondary end point (HR 0.758; 95% CI 0.581,
0.988) and of an ad-hoc major adverse CV
events composite end point of CV death, MI,
and stroke (HR 0.772; 95% CI 0.543, 1.097) were
consistent with the primary end point results.
These findings suggest that there is no increase
in CV risk associated with dapagliflozin in an
updated CV risk analysis that includes more
patients and a substantial proportion of older
patients ([20%) and patients with established
CVD ([30%). Although these results are
encouraging, presently the evidence is lacking
regarding macro and micro-vascular
complications of T2DM in patients managed
with this class of drugs. A randomized-
controlled clinical trial is already underway to
explore the long-term CV outcomes in patients
on treatment with SGLT2i as primary end point
[26].
Uric acid levels, a marker of metabolic
dysfunction, are markedly reduced (5.9–17.8%)
by SGLT2i, with the effect sustained for 2 years
[27]. The drugs may affect uric acid excretion
directly, by acting on its transport system, or
indirectly, but reducing sodium reabsorption in
the PCT. The beneficial impact of SGLT2i on
uric acid is attenuated if insulin is co-prescribed.
Renal hyperfiltration has been found to be
closely associated with the development of
diabetic nephropathy (DN) [28]. Pooled data
from 2 randomized clinical trials including 600
patients with normo- or microalbuminuria
followed up for 4 years which demonstrated
that hyperfiltration has central role in
pathogenesis of DN [28]. SGLT2 is one of the
main determinants of glomerular
hyperfiltration and blockade of SGLT2 has
potential nephroprotective action.
POSOLOGY
Dapagliflozin is approved as 10 mg once-daily
drug, as monotherapy, or as add-on to
metformin, sulfonylurea (SU), dipeptidyl
peptidase-4 (DPP-4) inhibitors, and/or insulin.
It can be prescribed alone to persons who do
not tolerate or cannot take metformin safely. A
5-mg dose is available for persons with hepatic
insufficiency. In mild to moderate hepatic
impairment, no dosage adjustment is required.
However, in severe hepatic impairment, 5 mg
starting dose is recommended [29].
Canagliflozin has a two-stage dosage regime.
The starting dose approved is 100 mg once
daily, before the first meal of the day. In those
who do not respond adequately, the dose can be
increased to 300 mg, provided renal function is
normal [10].
Empagliflozin is being studied in daily doses
of 10 and 25 mg. Trials have revealed dose-
dependent HbA1c reductions with
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empagliflozin monotherapy, which are greater
as compared to those observed with sitagliptin,
but similar to those experienced with
metformin. Empagliflozin can be administered
without relation to meal timings, in a once-
daily frequency [30].
Ipragliflozin has Japanese approval for the
treatment of T2DM, either alone or in
combination with metformin, pioglitazone,
SU, a-glucosidase inhibitor, DPP-4 inhibitor, or
with nateglinide [30].
ADVERSE EVENTS
The incidence of adverse events in clinical trials
of SGLT2i is similar to that observed with other
anti-diabetic drugs. The overall incidence of
adverse events has ranged from 57.3 to 83.0%,
while that of serious adverse events have varied
between 1.0% and 12.6% [31].
Uro-genital tract infections are the most
frequently noticed adverse events in subjects
on SGLT2i [32], especially in women and in
uncircumcised men. Pooled data from 12
placebo-controlled clinical trials of
dapagliflozin reveal that when used in dose
2.5, 5, and 10 mg per day, the incidence of
clinically diagnosed uro-genital tract infection
was 4.1%, 5.7% and 4.8%, respectively, while it
was 0.9% in the placebo group [33]. Common
infections include vulvitis and vulvo-vaginitis
in women, as well as balanitis and
balanoposthitis in men. These can be
prevented by maintaining adequate perineal
hygiene, and through treatment with
antifungal therapy. Genital infections are
thought to be caused by an increased glucose
load in the urinary tract, which encourages
fungal growth. The incidence of urinary tract
infections does not increase with SGLT2i
therapy [34].
The osmotic diuresis associated with SGLT2i
use also has the potential to cause volume
depletion and orthostatic hypotension. In
randomized-controlled trials, however, the
incidence of these adverse events has been
minimal (\3%) [25]. All such events have been
mild to moderate in severity. The extra diuresis
experienced per day is 350–450 ml (one extra
void per day) [34], and does not cause nocturia.
The diuresis seen with SGLT2i may result in
slight transient increase in serum creatinine and
blood urea, with a corresponding fall in
glomerular filtration rate (GFR).
The risk of hypoglycemia is minimal with
SGLT2i, as they have a non-insulin-based
mechanism of action. However, hypoglycemia
may occur when these molecules are used in
complication with other anti-diabetic drugs,
including metformin. Four-year comparison
between dapagliflozin plus metformin and
glipizide plus metformin showed a tenfold
decrease in the incidence of hypoglycemic
episodes (5.4% and 51.5%, respectively) [13].
In this 208-week study, patients treated with
dapagliflozin plus metformin had 35
hypoglycemic events as compared to 1,191
events in glipizide plus metformin group.
Dose-down titration during first year was
required in 2.7% patients in the dapagliflozin-
treated group compared with 15.8% in the
glipizide-treated group. This finding is very
significant in light of the long-term
consequences of hypoglycemic episodes on the
physiology of patients and their compliance to
treatment.
Sodium-glucose co-transporter-2 inhibitors
use leads to a slight reduction in bone
formation, and a rise in bone resorption
markers, although there are no major changes
on bone mineral density. A 102-week study
with dapagliflozin did not identify any changes
in markers of bone turnover as compared to
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placebo when added to metformin [27]. Other
long-term studies have not demonstrated any
significant increase in adverse drug reactions
related with skeletal system with any of the
SGLT2i [35, 36].
USE IN RENAL IMPAIRMENT
In patients with reduced GFR, the amount of
glucose reaching the PCT falls and the efficacy
of SGLT2 may be suboptimal. Canagliflozin is
prescribed in a full dose of 300 mg daily if GFR is
above 60 ml/min and as 100 mg once daily if
GFR is 45–60 ml/min [10]. Dapagliflozin can be
prescribed as 5 or 10 mg once daily, depending
upon the regulatory label in the country
concerned [29]. A pooled analysis of 13
clinical trials exploring the long-term renal
safety of dapagliflozin 10 mg as compared to
placebo or other oral hypoglycemic agents
showed no change in renal functions over a
period varying from 12 to 104 weeks [25].
Similarly, empagliflozin is being studied in
doses of 10 and 25 mg per day [37].
DRUG–DRUG INTERACTIONS
Sodium-glucose co-transporter-2 inhibitors do
not exhibit any clinically relevant drug–drug
interactions, including with other anti-diabetic
drugs and diuretics. They can be combined with
metformin, SU, pioglitazone, sitagliptin, and
voglibose. Concomitant prescription of loop
diuretics and SGLT2i should be avoided
because of the potential risk for volume
depletion. Co-administration of canagliflozin
with UGT-inducer drugs, for example,
rifampicin, phenytoin, phenobarbitone, and
ritonavir, should prompt an increase in dose
from 100 to 300 mg, if otherwise tolerated [10].
UGT enzyme-inducing agents increase the
metabolism of canagliflozin thus leading to a
decrease in peak plasma levels and reduced
efficacy [32].
CLINICAL USE
Current management of diabetes is
characterized by opportunities, options, and
obstacles. In spite of the availability of a wide
array of oral and injectable options, it remains
difficult to achieve good glycemic control,
while avoiding hypoglycemia and weight gain,
and ensuring CV safety. These adverse effects
are obstacles to the optimal use of
pharmaceuticals options currently available.
Sodium-glucose co-transporter-2 inhibitors
are a novel class of drugs with a novel
mechanism of action, which can be useful in
almost every stage of the natural history of
diabetes, and represent a means of achieving
better and safer glycemic control.
Sodium-glucose co-transporter-2 inhibitors
can be used as initial monotherapy in persons
in whom metformin is not indicated, or not
tolerated. Examples include those with hepatic
impairment and gastrointestinal intolerance.
SGLT2i can also be used as second-line drugs,
and third-line drugs, in persons inadequately
controlled on a single or dual glucose-lowering
therapy. Their glucose-lowering effect may help
some people with diabetes delay insulin
injections. Additionally, a significantly low risk
of hypoglycemia with these agents can improve
outcomes and compliance considerably.
The pleiotropic effects of SGLT2i—weight
loss, BP reduction, and uricosuria—make them
especially attractive for use in persons with
metabolic syndrome, and in those with mild
fluid overload. Their oral mode of
administration may favor their use over the
injectable glucagon-like peptide-1 receptor
agonists.
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This class of drugs can also be used in
combination with insulin, and its insulin-
sparing effect allows for more effective, well-
tolerated glycemic control, without weight
gain. A 24-week clinical trial comparing
dapagliflozin versus placebo in patients taking
a high dose of insulin demonstrated a decrease
in insulin requirement of 0.79% and 0.39%,
respectively [38]. Additionally, there was a
significant decrease in insulin dose required by
patients treated with dapagliflozin as compared
to an increase in placebo group. A statistically
significant decrease in body weight of up to
2.4 kg in the dapagliflozin 10 mg group as
compared to an increase of 0.43 kg in the
placebo group was also seen [38].
The ability to prescribe SGLT2i to persons
with renal [39] and hepatic impairment, an easy
two-step or one-step dose titration, a lack of
relevant drug–drug interactions, and safety in
combination with all routinely used CV and
anti-diabetic drugs, are all points which will
encourage their use.
Counseling regarding potential side effects
and ways to prevent them, for example,
perineal hygiene and avoidance of volume
depletion, must accompany SGLT2i
prescription.
A recent pilot study explored the potential
role of SGLT2i in managing hyperglycemia
associated with type 1 diabetes mellitus
(T1DM) [40]. This 2-week exploratory study of
dapagliflozin in doses ranging from 1 to 10 mg
per day in addition to insulin, established its
safety and pharmacokinetics, and explored the
pharmacodynamics of a new class of drug for
managing T1DM. Glucosuria increased by
88 mg/day in the dapagliflozin group while it
decreased by 21.5 mg/day in the placebo group.
Additionally, a fall of 16.2% in the dapagliflozin
group and an increase of 1.7% in the placebo
group for total daily insulin dose were seen
during this period [40]. More proof-of-concept
studies are available documenting reno-
protection provided by these agents in T1DM.
Renal hyperfiltration which is an early
hemodynamic abnormality preceding frank
nephropathy in T1DM was improved with
short-term use of these agents [41, 42]. Newer
SGLT2i, still in pre-clinical and clinical phases
of development, are expected to have a safer
profile in view of their highly selective action
[43, 44].
CONCLUSION
The SGLT2i represent a novel class of drugs
which will certainly help a large number of
people with diabetes achieve target control in a
safe and well-tolerated manner. Their unique
mechanism of action, coupled with pleiotropic
benefits on weight and blood pressure, should
make them attractive choices for add-on
therapy to persons not controlled on other
medications.
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